Primary Immunodeficiency Disease Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Pharmacokinetics, Safety and Tolerability, and Efficacy Evaluation of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Condition: Primary Immunodeficiency Diseases (PID) Interventions: Biological: Immune Globulin Intravenous (IGIV); Biological: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) Sponsor: Baxalta now part of Shire Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2020 Category: Research Source Type: clinical trials
